Similar to Golfyeti's question.....I would be interested in hearing an answer from management as to when we will hear about the pre-specified sub-group analyses of the primary outcome and the likelihood that a successful sub-group analysis (i.e. rosuvastatin) would be supportive of NDA approval.

Pre-specified subgroup analyses for the primary endpoint include:

– Rosuvastatin/Atorvastatin

– < 30 days/> 30 days post-acute coronary syndrome

– LDL/HDL/TG’s above and below median

– HbA1c above and below median

– eGFR >60 mL/min and < 60 mL/min